Tailored Exercise to Reduce Aromatase Inhibitor Associated Musculoskeletal Symptoms
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: tailored exercise.
- Who it may be relevant to
- Registry conditions: Patients With Early Breast Cancer Who Initiating Adjuvant Aromatase Inhibitor. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Thailand
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effectiveness of Tailored Home-based Exercise on Aromatase Inhibitor-associated Musculoskeletal Symptoms in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitor: A Randomized, Controlled Trial
Overview
A randomized controlled study evaluating effect of tailored exercise compared to routine practice as a preventive measure of aromatase inhibitor associated musculoskeletal related symptoms in early breast cancer patients
Interventions
- Behavioral tailored exercise
tailored suitable exercise to individuals recommended for the aim of aerobic exercise at 150 minutes per week and strengthening exercise twice a week
Primary outcome measures
- Aromatase inhibitor associated musculoskeletal symptoms (AIMSS) [Time frame: 12 months]
Secondary outcome measures (3)
- worsening pain [Time frame: 12 months]
- body weight [Time frame: 12 months]
- quality of life FACT-ES [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- breast cancer patients with starting adjuvant aromatase inhibitor within 4 weeks
- able to read and write
Exclusion criteria
- chronic arthritis
- history of heart failure or acute coronary syndrome within 6 months
- individuals who exercises regularly more than 150 minutes/week
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
Thailand · 1 center
- Faculty of Medicine Siriraj Hospital, Mahidol University — Bangkok
Publications
- Lu G, Zheng J, Zhang L. The effect of exercise on aromatase inhibitor-induced musculoskeletal symptoms in breast cancer survivors :a systematic review and meta-analysis. Support Care Cancer. 2020 Apr;28(4):1587-1596. doi: 10.1007/s00520-019-05186-1. Epub 2019 Dec 18. PMID 31853701
- Roberts KE, Adsett IT, Rickett K, Conroy SM, Chatfield MD, Woodward NE. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer. Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD013167. doi: 10.1002/14651858.CD013167.pub2. PMID 35005781
- Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P, Li L, Flockhart D, Stearns V, Hayes DF, Storniolo AM, Clauw DJ. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008 Sep;111(2):365-72. doi: 10.1007/s10549-007-9774-6. Epub 2007 Oct 6. PMID 17922185
Identifiers
NCT: NCT07448558 · 1171/2568(IRB3)